My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

58.51 -0.10 (-0.17%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗

July 22, 2025

AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.

Via Benzinga

Topics Government

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.

Via Benzinga

Topics Government World Trade

Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing' ↗

July 11, 2025

Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.

Via Benzinga

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround ↗

July 07, 2025

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY stock.

Via Benzinga

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment? ↗

June 30, 2025

The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.

Via Investor's Business Daily

Trump Vows To Cut 'The Best Deal' On Drug Prices. What To Expect. ↗

June 26, 2025

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy.

Via Investor's Business Daily

Topics Government

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗

June 23, 2025

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Via Benzinga

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗

June 23, 2025

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.

Via Benzinga

Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗

June 23, 2025

Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study.

Via Investor's Business Daily

Two Biotech Stocks Poised For Big Moves On Monday ↗

June 23, 2025

Via Benzinga

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars ↗

June 18, 2025

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Via Stocktwits

Roche Stock Slides After Failed Blood Cancer Trial With AbbVie, But Parkinson’s Therapy Progress Boosts Retail Mood ↗

June 16, 2025

The Swiss pharma giant advanced its anti-alpha-synuclein antibody prasinezumab to the next stage based on promising Phase IIb data.

Via Stocktwits

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy ↗

June 16, 2025

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Via Benzinga

Topics Death

Eli Lilly's Obesity Drug Success Spurs Japanese Biotech's Anti-Muscle-Wasting Combo Therapy ↗

June 09, 2025

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.

Via Benzinga

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study ↗

June 03, 2025

Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients.

Via Benzinga

How AstraZeneca Is Playing Its Cancer Cards To Become An $80 Billion Pharma ↗

June 02, 2025

Three new cancer drugs could help make a dent in the company's ambitious plans for 2030.

Via Investor's Business Daily

Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years ↗

May 30, 2025

Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients over 96 weeks.

Via Benzinga

Roche Gets Positive Opinion For Approval Of Cancer Therapy In EU: Retail Yet To React ↗

May 23, 2025

The company said that the European Commission is expected to make a decision soon regarding the approval for Itovebi.

Via Stocktwits

Topics Government

The Smartest Vanguard ETF to Buy With $500 Right Now ↗

May 21, 2025

Via The Motley Fool

Topics ETFs

Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price ↗

May 16, 2025

Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition.

Via Investor's Business Daily

Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda ↗

May 15, 2025

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.

Via Benzinga

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases ↗

May 14, 2025

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.

Via Benzinga

Why Weight-Loss Developer Stocks Tumbled on Tuesday ↗

May 13, 2025

Via The Motley Fool

Topics Government

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17% ↗

May 13, 2025

Roche's APHINITY study shows promising results for HER2-positive breast cancer treatment with Perjeta regime

Via Benzinga

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗

May 12, 2025

It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices.

Via Investor's Business Daily

Topics Government Stocks

Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots ↗

May 12, 2025

Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.

Via Benzinga

Topics Artificial Intelligence

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket ↗

May 12, 2025

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription...

Via Benzinga

Topics Government

< Previous 1 2 3 4 5 6 7 8 9

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.